HC Wainwright Has Negative Outlook of PCSA FY2024 Earnings

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Processa Pharmaceuticals in a research report issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($4.05) for the year, down from their prior forecast of ($3.78). HC Wainwright currently has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Processa Pharmaceuticals’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q4 2024 earnings at ($0.92) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.16) EPS.

Processa Pharmaceuticals Stock Up 6.4 %

Shares of NASDAQ:PCSA opened at $1.33 on Monday. Processa Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $17.40. The stock has a market capitalization of $4.35 million, a P/E ratio of -0.37 and a beta of 0.66. The firm has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.47.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.